Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coronado nabs preclinical cancer assets from NeuPharma

This article was originally published in Scrip

Executive Summary

After a restructuring of the company a little more than a year ago, Coronado Biosciences is continuing to add to its pipeline portfolio – the biotech struck a deal with NeuPharma on 19 March for an undisclosed number of preclinical cancer assets. Coronado agreed to pay an undisclosed up front fee, as well as development- and sales-based milestones. Coronado also agreed to single-digit sales royalties on any products that result. The biotech will develop and commercialize irreversible, third-generation epidermal growth factor receptor (EGRF) inhibitors worldwide, except for Asian countries. The deal comes about a year after Coronado's lead therapy – a treatment for Crohn's disease developed using parasitic worms – failed in Phase II trials to show any effectiveness beyond a placebo (, 14 October 2013). The clinical trial failure forced Coronado to pare down the company (, 08 November 2013).

You may also be interested in...

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Zafgen Drops Beloranib, But Its New Focus Raises Doubts

The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.

Update: Ziopharm Study Death Not Due To Drug

The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts